Clinical Trials

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04652960 2026-03-18

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

38 enrolled

Mycosis Fungoides, Sezary Syndrome

NCT05272384 2026-03-18

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

32 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05627245 2026-03-18

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT06860594 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06904066 2026-03-18

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

86 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07332507 2026-03-18

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Plasmablastic Lymphoma

NCT07388563 2026-03-18

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

20 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07478848 2026-03-18

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

14 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02160015 2026-03-17

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03528642 2026-03-17

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

40 enrolled

CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Phase 1 Terminated

84 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05397496 2026-03-17

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

61 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07164560 2026-03-17

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

45 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05131022 2026-03-16

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

572 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

24 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06254495 2026-03-16

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

57 enrolled

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-03-16

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07137494 2026-03-16

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

12 enrolled

Lymphoma, Recurrence

NCT02390752 2026-03-13

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

CNSLymphoidOther hematologic neoplasmSarcoma

54 enrolled

Sarcoma, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

453 enrolled

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT05424822 2026-03-13

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

167 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05784441 2026-03-13

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

21 enrolled

Recurrence, Lymphoma, B-Cell

NCT06139406 2026-03-13

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

70 enrolled

Lymphoma, Non-Hodgkin

NCT06470438 2026-03-13

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

58 enrolled

Lymphoma, Non-Hodgkin

NCT06660563 2026-03-13

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

19 enrolled

Lymphoma, Non-Hodgkin

NCT06875063 2026-03-13

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

26 enrolled

Burkitt Lymphoma

NCT07295951 2026-03-13

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

10 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07308132 2026-03-13

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

130 enrolled

Lymphoma, Non-Hodgkin

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05828589 2026-03-12

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

112 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05994157 2026-03-12

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled

Lymphoma, Non-Hodgkin

NCT07465835 2026-03-12

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

84 enrolled

Lymphoma

NCT01087294 2026-03-11

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Completed

85 enrolled